...the compound in dog models of sarcoma. Eisai Co. Ltd., Bausch Health Companies Inc. and Minophagen Pharmaceutical Co. Ltd....

...testing the compounds in animal models of breast and lung cancer. Eisai Co. Ltd. , Minophagen Pharmaceutical Co. Ltd....

...for combining DHA and bexarotene in clinical trials to treat AD. Eisai Co. Ltd. , Minophagen Pharmaceutical Co. Ltd....

...America. Eisai acquired Targretin from Ligand Pharmaceuticals Inc. (NASDAQ:LGND, La Jolla, Calif.) in October 2006. Minophagen Pharmaceutical Co. Ltd....

...Eisai granted Minophagen exclusive rights to develop and commercialize Targretin bexarotene to treat cutaneous T cell...
...to co-commercialize the product in the territories. Details were not disclosed. Last year, Eisai granted Minophagen...
...Ligand Pharmaceuticals Inc. (NASDAQ:LGND, La Jolla, Calif.) in October 2006 (see BioCentury, Sept. 11, 2006). Minophagen Pharmaceutical Co. Ltd....

...Eisai granted Minophagen exclusive rights to develop and commercialize Targretin bexarotene in Japan. Eisai retains an...
...to treat recurrent or refractory cutaneous T cell lymphoma (CTCL). Financial terms were not disclosed. Minophagen Pharmaceutical Co. Ltd....

...onepharm received exclusive rights to develop and market Minophagen's OPM-3001 in Europe and the U.S. to...
...to start a Phase II trial of the compound derived from licorice root in 2008. Minophagen...
...of glycyrrhizin, an extract derived from licorice root, to treat chronic HCV infection in Asia. Minophagen Pharmaceutical Co. Ltd....